Fisher & Paykel Healthcare Corporation Ltd
NZX:FPH
Intrinsic Value
Fisher & Paykel Healthcare Corp. Ltd. engages in the designing, manufacturing and marketing of medical device products and systems for use in respiratory care, acute care and the treatment of obstruct... [ Read More ]
The intrinsic value of one
FPH
stock under the Base Case scenario is
16.97
NZD.
Compared to the current market price of 26.78 NZD,
Fisher & Paykel Healthcare Corporation Ltd
is
Overvalued by 37%.
Fisher & Paykel Healthcare Corporation Ltd's market capitalization is 15.5B NZD.
FPH stock price is 26.78 NZD.
FPH stock (16.97 NZD) is 37% less than its price (26.78 NZD).
FPH has downside potential of 7% compared to the average analyst price target.
Open Wall St Estimates
FPH's Revenue has been growing by 2% per year for the last 3 years.
FPH's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 13%.
FPH's Revenue has grown by 15% over the past 12 months.
FPH's ROE (Return on Equity) for the past 12 months is positive and is equal to 16%.
FPH's Revenue is forecast to grow at a rate of 12% per year over the next 3 years.
FPH has positive Net Income for the last twelve months.
FPH has positive Free Cash Flow for the last twelve months.
FPH has positive Operating Income for the last twelve months.
FPH's ROE (Return on Equity) has significantly decreased in the last 3 years from 42% to 16%.
FPH's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 40% to 13%.
FPH has positive three-year average ROIC (Return on Invested Capital): 25%. The company is efficient at using invested capital to generate operating income.
FPH has very high three-year average ROE (Return on Equity): 27%. The company is very efficient at transforming stockholders' equity into net income.
FPH's short-term assets (729m NZD) exceed its short-term liabilties (287m NZD).
FPH has positive Net Debt. This means that the company has more debt (300m NZD) than cash and short-term investments (71m NZD).
FPH has positive Gross Profit for the last twelve months.
FPH's D/E (Debt to Equity) is very low and is equal to 0.17.
FPH's long-term assets (2B NZD) exceed its long-term liabilties (638m NZD).
FPH's Altman Z-Score is very high and is equal to 13.99.
FPH doesn't generate enough operating income (358m NZD) to safely cover interest payments on its debt (-15m NZD).
Valuation Backtest
Fisher & Paykel Healthcare Corporation Ltd
Run backtest to discover the historical profit from buying and selling
FPH
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Fisher & Paykel Healthcare Corporation Ltd
Balance Sheet Decomposition
Fisher & Paykel Healthcare Corporation Ltd
| Current Assets | 729.2m |
| Cash & Short-Term Investments | 70.5m |
| Receivables | 261.9m |
| Other Current Assets | 396.8m |
| Non-Current Assets | 1.7B |
| PP&E | 1.4B |
| Intangibles | 85.5m |
| Other Non-Current Assets | 155.7m |
| Current Liabilities | 286.8m |
| Accounts Payable | 212.7m |
| Other Current Liabilities | 74.1m |
| Non-Current Liabilities | 351.2m |
| Long-Term Debt | 299.6m |
| Other Non-Current Liabilities | 51.6m |
Earnings Waterfall
Fisher & Paykel Healthcare Corporation Ltd
|
Revenue
|
1.7B
NZD
|
|
Cost of Revenue
|
-682.9m
NZD
|
|
Gross Profit
|
1B
NZD
|
|
Operating Expenses
|
-653.2m
NZD
|
|
Operating Income
|
358.1m
NZD
|
|
Other Expenses
|
-96.4m
NZD
|
|
Net Income
|
261.7m
NZD
|
Free Cash Flow Analysis
Fisher & Paykel Healthcare Corporation Ltd
What is Free Cash Flow?
FPH Profitability Score
Profitability Due Diligence
Fisher & Paykel Healthcare Corporation Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Fisher & Paykel Healthcare Corporation Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
FPH Solvency Score
Solvency Due Diligence
Fisher & Paykel Healthcare Corporation Ltd's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Fisher & Paykel Healthcare Corporation Ltd's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FPH Price Targets Summary
Fisher & Paykel Healthcare Corporation Ltd
According to Wall Street analysts, the average 1-year price target for
FPH
is 24.84 NZD
with a low forecast of 21.72 NZD and a high forecast of 29.93 NZD.
Shareholder Return
FPH Price
Fisher & Paykel Healthcare Corporation Ltd
| Average Annual Return | 17.92% |
| Standard Deviation of Annual Returns | 38.85% |
| Max Drawdown | -50% |
| Market Capitalization | 15.5B NZD |
| Shares Outstanding | 583 964 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Fisher & Paykel Healthcare Corporation Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Fisher & Paykel Healthcare Corp. Ltd. engages in the designing, manufacturing and marketing of medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The firm offers its products across hospital and homecare settings. The Company’s hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, and laparoscopic and open surgery. Its homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home, which include the Company’s continuous positive airway pressure (CPAP) therapy masks, as well as flow generators, interfaces, and data management technologies. The firm operates across Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, India, Germany, Austria, Italy, Turkey, China, Hong Kong, Taiwan, Malaysia, Singapore and Australia.
Contact
IPO
Employees
Officers
The intrinsic value of one
FPH
stock under the Base Case scenario is
16.97
NZD.
Compared to the current market price of 26.78 NZD,
Fisher & Paykel Healthcare Corporation Ltd
is
Overvalued by 37%.
You don't have any saved screeners yet
